Download pdf
The Applications of CRISPR Systems in Cancer Detection
- 1 School of Medicine, Hunan Normal University, Changsha,410000, China
* Author to whom correspondence should be addressed.
Abstract
With the increasing incidence and mortality rate of cancer, CRISPR technology needs to be applied more widely and accurately in this field. The current application of CRISPR in cancer detection is mostly aimed at cancers with clear genes as tumor markers. The detection of some cancers with unknown pathogenesis is still in the stage of development. Studying their pathogenesis through CRISPR technology may make progress and accelerate their detection and diagnosis. This article demonstrates the feasibility of CRISPR cas system and the incidence detection principles of the important disease cancer and introduces representative application cases to further demonstrate the importance and development prospects of CRISPR in this field. This article helps to gain a preliminary understanding of the application principles of CRISPR system in cancer detection, facilitating the screening of suitable related technologies and providing ideas for future study on new CRISPR technologies in cancer. In the future, CRISPR technology is highly likely to greatly accelerate the speed of cancer detection, reduce detection costs, and provide assistance for integrated cancer detection, perhaps making cancer detection as easy as nucleic acid kit testing.
Keywords
Cancer, CRISPR, detection
[1]. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263.
[2]. Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022). CRISPR in cancer biology and therapy. Nature Reviews Cancer, 22(5), 259–279.
[3]. Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019). CRISPR/Cas9 for cancer research and therapy. In Seminars in Cancer Biology (Vol. 55, pp. 106–119). Academic Press.
[4]. Moses, C., Garcia-Bloj, B., Harvey, A. R., & Blancafort, P. (2018). Hallmarks of cancer: The CRISPR generation. European Journal of Cancer, 93, 10–18.
[5]. Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001). EGFR and cancer prognosis. European Journal of Cancer, 37, 9–15.
[6]. Dong, Y. W., Hou, J. H., Zhu, B. C., Li, P. Q., & Pang, Y. H. (2005). Concepts and research progress in epigenetics. Journal of Biology, 22(1), 1–3.
[7]. Jablonka, E., & Lamb, M. J. (2002). The changing concept of epigenetics. Annals of the New York Academy of Sciences, 981(1), 82–96.
[8]. Li, G. L., Yu, S. X., Fan, S. L., Song, M. Z., & Pang, C. Y. (2011). Research progress in epigenetics. Biotechnology Bulletin, (1), 40.
[9]. Gibney, E. R., & Nolan, C. M. (2010). Epigenetics and gene expression. Heredity, 105(1), 4–13.
[10]. Mustafa, M. I., & Makhawi, A. M. (2021). SHERLOCK and DETECTR: CRISPR-Cas systems as potential rapid diagnostic tools for emerging infectious diseases. Journal of Clinical Microbiology, 59(3), 10–1128.
[11]. Pickar-Oliver, A., & Gersbach, C. A. (2019). The next generation of CRISPR–Cas technologies and applications. Nature Reviews Molecular Cell Biology, 20(8), 490–507.
Cite this article
Li,X. (2025). The Applications of CRISPR Systems in Cancer Detection. Theoretical and Natural Science,82,45-51.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 3rd International Conference on Modern Medicine and Global Health
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).